Andy Crockett, CEO

Andy joined Vantia in 2009 from the US specialty pharma company Zars Pharma where he was most recently VP Business Development. During his career he has identified, negotiated and executed strategic corporate transactions on a global basis, including merger and acquisitions, national and international product licences, IP and technology licences, and R&D alliances.

Andrew has studied at Harvard Business School and also holds an MBA from The Wharton School, University of Pennsylvania, with a major in Finance.

Stephen Donnelly, CFO

Stephen has over ten years of experience working with healthcare companies. He holds professional accounting and company secretarial qualifications and previous positions in the industry include Chief Accountant/Company Secretary for Anagen PLC, a diagnostic company quoted on the LSE, and CFO/Company Secretary of Alfa Biotech (UK) Limited, a UK subsidiary of an Italian pharmaceutical company. Stephen has also had a senior management role with other venture capital healthcare companies including Novarticulate Holdings Ltd. and Rodaris Pharmaceuticals Ltd. In addition to these roles in the healthcare industry he also held the position of Director of Finance and Administration for the London Office of The Nasdaq Stock Market Inc.

Robert Haigh, CSO

Robert holds a Masters in Biochemistry and a PhD in Medicine both from Manchester University. Following a successful Research Fellowship at Oxford University, he began his pharmaceutical career in drug discovery and has held positions of increasing responsibility in R&D during a 17 year career with Boehringer Ingelheim and Ferring Pharmaceuticals.

As Managing Director and VP Research, Robert transformed Ferring Research Ltd from an academic research institute into a productive pharmaceutical research centre and in 2008 he led the spin-out of the site.

During his career, he has lived and worked in the UK and Germany and has held board level positions in Europe and the USA.

Robert is a Founder of Vantia Therapeutics.

Hilary McElwaine-Johnn, CMO

Hilary is a medical graduate from St Mary's Hospital Medical School, London and has a first class BSc degree from Imperial College London.

She is a Member of the Royal College of Physicians (MRCP) and the Faculty of Pharmaceutical Medicine (MFPM).

Hilary first started working in the Pharmaceutical Industry in 1993 with Servier Research & Development Ltd. Whilst at Servier she gained experience in the clinical development of small molecules as well as in medico-marketing and management. In 2002 she joined PowderJect as Associate Medical Director working across the development and commercial disciplines with vaccines and biologics. She was subsequently Medical Director of Chiron Vaccines UK.

Hilary joined PowderMed Ltd at its inception in May 2004 as Vice President Clinical. In this role she assumed responsibility for the design and delivery of PowderMed's clinical development programs up to the company's full acquisition by Pfizer Inc.

Hilary joined Vantia as CMO in June 2008.

Rachel Morten, Head of Regulatory Affairs

Rachel has more than 24 years experience in global regulatory affairs and product development in the pharmaceutical and animal health industries. Most recently an independent regulatory affairs consultant, Rachel has also served as Senior Director, Group Head Regulatory Affairs for the international CRO Averion International Ltd (previously Hesperion). Previously Rachel founded ChapelPharma a regulatory consultancy that was acquired by Hesperion in 2004.

Rachel joined Vantia in 2009.

Chris Yea, Business Development Director